Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2013 1
2018 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.
Galimberti V, Cole BF, Viale G, Veronesi P, Vicini E, Intra M, Mazzarol G, Massarut S, Zgajnar J, Taffurelli M, Littlejohn D, Knauer M, Tondini C, Di Leo A, Colleoni M, Regan MM, Coates AS, Gelber RD, Goldhirsch A; International Breast Cancer Study Group Trial 23-01. Galimberti V, et al. Lancet Oncol. 2018 Oct;19(10):1385-1393. doi: 10.1016/S1470-2045(18)30380-2. Epub 2018 Sep 5. Lancet Oncol. 2018. PMID: 30196031 Clinical Trial.
Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.
Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, Baratella P, Chifu C, Sargenti M, Intra M, Gentilini O, Mastropasqua MG, Mazzarol G, Massarut S, Garbay JR, Zgajnar J, Galatius H, Recalcati A, Littlejohn D, Bamert M, Colleoni M, Price KN, Regan MM, Goldhirsch A, Coates AS, Gelber RD, Veronesi U; International Breast Cancer Study Group Trial 23-01 investigators. Galimberti V, et al. Among authors: recalcati a. Lancet Oncol. 2013 Apr;14(4):297-305. doi: 10.1016/S1470-2045(13)70035-4. Epub 2013 Mar 11. Lancet Oncol. 2013. PMID: 23491275 Free PMC article. Clinical Trial.
Coping strategies for COVID-19 primary care: a mixed method study.
Barbieri J, Recalcati ADS, Ramos AR, Santos AMD, Magalhães AMM, Riquinho DL. Barbieri J, et al. Among authors: recalcati ads. Cien Saude Colet. 2023 Sep;28(9):2613-2623. doi: 10.1590/1413-81232023289.16392022. Epub 2023 Feb 2. Cien Saude Colet. 2023. PMID: 37672451 Free article. English, Portuguese.
Avoiding axillary dissection in breast cancer surgery: a randomized trial to assess the role of axillary radiotherapy.
Veronesi U, Orecchia R, Zurrida S, Galimberti V, Luini A, Veronesi P, Gatti G, D'Aiuto G, Cataliotti L, Paolucci R, Piccolo P, Massaioli N, Sismondi P, Rulli A, Lo Sardo F, Recalcati A, Terribile D, Acerbi A, Rotmensz N, Maisonneuve P. Veronesi U, et al. Among authors: recalcati a. Ann Oncol. 2005 Mar;16(3):383-8. doi: 10.1093/annonc/mdi089. Epub 2005 Jan 24. Ann Oncol. 2005. PMID: 15668261 Free article. Clinical Trial.
Single-agent epirubicin as primary chemotherapy in T2-T3, N0-N2, M0 breast carcinoma: 6-year follow-up.
Barni S, Piazza E, Frontini L, Visini M, Ardizzoia A, Grassi MM, Nosenzo MA, Mandalà M, Biasioli R, Freddi E, Lucani L, Recalcati A, Pravettoni A, Sala R, Rezzani C, Villa S, Trabucchi E; Neo-Adjuvant Breast Italian Group. Barni S, et al. Among authors: recalcati a. Oncology. 2004;67(1):40-7. doi: 10.1159/000080284. Oncology. 2004. PMID: 15459494 Clinical Trial.